Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma - PubMed (original) (raw)
. 1997 Oct 15;57(20):4608-14.
Affiliations
- PMID: 9377576
Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma
M H Dreyling et al. Cancer Res. 1997.
Abstract
Mantle cell lymphoma (MCL) has recently become generally accepted as a subentity of malignant lymphomas that is characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in the overexpression of cyclin D1. Cyclin D1 forms a complex with cell cycle-dependent kinase (cdk) 4, which inactivates the retinoblastoma protein (pRB) via phosphorylation. However, in transgenic mice, the overexpression of cyclin D1 alone is not sufficient for the development of malignant lymphoma. To determine whether other members of the pRB pathway contribute to the malignant transformation of MCL, we analyzed 37 cases of MCL that were well characterized by morphology, immunophenotype, and/or interphase cytogenetics [detection of t(11;14)(q13;q32)]. Interphase fluorescence in situ hybridization was performed using a cosmid contig (250 kb) of the CDKN2/p16 region (encoding an inhibitor of the cyclin D1/cdk4 complex) and a phage contig (200 kb) of the Rb region. CDKN2/p16 deletion was detected in 15 cases (41%), including 6 homozygous deletions; Rb was deleted in 15 cases (41%), all of which were hemizygous deletions. Nine cases (24%) had deletions of both CDKN2/p16 and Rb. Further analysis of a subset of 17 MCLs revealed a highly significant correlation between CDKN2/p16 deletion and proliferation index, determined by the rate of Ki67 expression (P = 0.014; t test). No significant correlation was found between CDKN2/p16 deletion and the blastoid variant of MCL (P = 0.23; Fisher's test) or between proliferation index and blastoid morphology (P = 0.51; t test). Deletion of Rb did not have any impact on cell proliferation in addition to CDKN2/p16 deletion (P = 0.76; t test). Additional analysis of 13q14 deletions suggests that these deletions may target another gene telomeric to Rb. We conclude that deletion of CDKN2/p16 occurs in approximately one-half of MCLs and is a more relevant indicator of the proliferative features as compared to morphological criteria. In contrast, although deletions of chromosomal band 13q14 are frequent in MCL, inactivation of Rb seems not to be involved in the pathogenesis of MCL.
Similar articles
- Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.
Krämer A, Schultheis B, Bergmann J, Willer A, Hegenbart U, Ho AD, Goldschmidt H, Hehlmann R. Krämer A, et al. Leukemia. 2002 Sep;16(9):1844-51. doi: 10.1038/sj.leu.2402609. Leukemia. 2002. PMID: 12200702 - CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. Ueki K, et al. Cancer Res. 1996 Jan 1;56(1):150-3. Cancer Res. 1996. PMID: 8548755 - Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
Sartor M, Steingrimsdottir H, Elamin F, Gäken J, Warnakulasuriya S, Partridge M, Thakker N, Johnson NW, Tavassoli M. Sartor M, et al. Br J Cancer. 1999 Apr;80(1-2):79-86. doi: 10.1038/sj.bjc.6690505. Br J Cancer. 1999. PMID: 10389982 Free PMC article. - Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma.
Dreyling MH, Roulston D, Bohlander SK, Vardiman J, Olopade OI. Dreyling MH, et al. Genes Chromosomes Cancer. 1998 May;22(1):72-8. Genes Chromosomes Cancer. 1998. PMID: 9591637 Review. - Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V, Hartmann E, Ott G, Campo E, Rosenwald A. Fernàndez V, et al. J Clin Oncol. 2005 Sep 10;23(26):6364-9. doi: 10.1200/JCO.2005.05.019. J Clin Oncol. 2005. PMID: 16155021 Review.
Cited by
- The biology of human lymphoid malignancies revealed by gene expression profiling.
Staudt LM, Dave S. Staudt LM, et al. Adv Immunol. 2005;87:163-208. doi: 10.1016/S0065-2776(05)87005-1. Adv Immunol. 2005. PMID: 16102574 Free PMC article. Review. - CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity.
Bonelli P, Tuccillo FM, Borrelli A, Schiattarella A, Buonaguro FM. Bonelli P, et al. Biomed Res Int. 2014;2014:361020. doi: 10.1155/2014/361020. Epub 2014 Jan 29. Biomed Res Int. 2014. PMID: 24605326 Free PMC article. Review. - Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
Restelli V, Lupi M, Vagni M, Chilà R, Bertoni F, Damia G, Carrassa L. Restelli V, et al. Target Oncol. 2018 Apr;13(2):235-245. doi: 10.1007/s11523-018-0553-6. Target Oncol. 2018. PMID: 29441438 - Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications.
Mostaghel EA, Martin PS, Mongovin S, Frayo S, Zhang A, Edlefsen KL, Press OW, Gopal AK. Mostaghel EA, et al. Exp Hematol. 2017 May;49:34-38.e2. doi: 10.1016/j.exphem.2017.01.001. Epub 2017 Jan 21. Exp Hematol. 2017. PMID: 28115200 Free PMC article. - Mantle cell lymphoma is characterized by inactivation of the ATM gene.
Schaffner C, Idler I, Stilgenbauer S, Döhner H, Lichter P. Schaffner C, et al. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2773-8. doi: 10.1073/pnas.050400997. Proc Natl Acad Sci U S A. 2000. PMID: 10706620 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous